NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the presentation of three posters on plecanatide and SP-333 to be given at the 2011 annual scientific meeting of the American College of Gastroenterology which is being held in Washington, DC from October 28 to November 2, 2011. Plecanatide is currently being evaluated in a Phase II/III trial for chronic idiopathic constipation, and the drug is also being developed for treatment of constipation-predominant irritable bowel syndrome (IBS-C). SP-333, the Company’s second drug candidate, is being developed for treatment of inflammatory bowel diseases. The Company plans to file an IND for SP-333 in 2012.
The dates and times for these poster presentations are as follows:
Monday October 31, 10:30 am to 4:30 pm
Poster P409: Guanylate Cyclase C Agonists as a New Class of Drug Candidates to Delay Progression of Colitis to Colonic Tumors in ApcMin/+ Mice. Kunwar Shailubhai1, Wen-Chi Chang3, Shet Masih2, Harry S. Cooper3, Margie L. Clapper3 1Synergy Pharmaceuticals, Doylestown, PA, 2Institute of Hepatitis Virus Research, Doylestown, PA, and 3Fox Chase Cancer Center, Philadelphia, PA, USA.
Tuesday November 1, 10:30 am to 4:30 pm
Poster P1124: Guanylate Cyclase C Agonists, a New Class of Drug Candidates for Treatment of Inflammatory Bowel Disease. Kunwar Shailubhai1, Bradley Nefsky2, John Foss1, Stephen S. Comiskey1, Gary S. Jacob1, Scott Plevy3. 1Synergy Pharmaceuticals, Doylestown, PA, 2Institute of Hepatitis Virus Research, Doylestown, PA, and 3University of North Carolina at Chapel Hill, Chapel Hill, NC.
Poster P1174: Plecanatide, a Guanylate Cyclase C Agonist, Improves Bowel Habits and Symptoms Associated with Chronic Constipation in a Phase IIa Clinical Study. Kunwar Shailubhai1, Laura Barrow2, Craig Talluto2, Stephen S. Comiskey1, John Foss1, Rong Feng1, Alan Joslyn2, Gary S. Jacob2. 1Synergy Pharmaceuticals, Doylestown, PA, USA. 2Synergy Pharmaceuticals, New York, NY, USA.
About Synergy Pharmaceuticals, Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. The company completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in CIC patients. In October, 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide to treat chronic idiopathic constipation. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome, with the first trial in IBS-C patients planned for 2012. Synergy’s second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.